Transcriptional regulation of HSCs in Aging and MDS reveals DDIT3 as a Potential Driver of Dyserythropoiesis

ABSTRACT

[1]  C. Mason,et al.  Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma , 2021, Leukemia.

[2]  E. Papaemmanuil,et al.  Epigenetic therapy of myelodysplastic syndromes connects to cellular differentiation independently of endogenous retroelement derepression , 2019, Genome Medicine.

[3]  K. Do,et al.  Transcriptomic analysis implicates necroptosis in disease progression and prognosis in myelodysplastic syndromes , 2019, Leukemia.

[4]  E. Campo,et al.  Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma , 2019, bioRxiv.

[5]  Hsuan-Ting Huang,et al.  Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia. , 2019, Cancer discovery.

[6]  A. Gavin,et al.  Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. , 2018, Blood.

[7]  Rui Chen,et al.  Distinct transcriptomic and exomic abnormalities within myelodysplastic syndrome marrow cells , 2018, Leukemia & lymphoma.

[8]  N. Taylor,et al.  Developmental differences between neonatal and adult human erythropoiesis , 2018, American journal of hematology.

[9]  Satoru Miyano,et al.  Gene expression and risk of leukemic transformation in myelodysplasia. , 2017, Blood.

[10]  B. Ebert,et al.  The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia , 2016, Nature Reviews Cancer.

[11]  K. Moore,et al.  Hematopoietic Stem Cells Count and Remember Self-Renewal Divisions , 2016, Cell.

[12]  K. Ghosh,et al.  Secretion and Expression of Matrix Metalloproteinase-2 and 9 from Bone Marrow Mononuclear Cells in Myelodysplastic Syndrome and Acute Myeloid Leukemia. , 2016, Asian Pacific journal of cancer prevention : APJCP.

[13]  Takuro Nakamura.  The role of Trib1 in myeloid leukaemogenesis and differentiation. , 2015, Biochemical Society transactions.

[14]  P. Nederkoorn,et al.  Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations , 2015, Pediatric Rheumatology.

[15]  J. Boultwood,et al.  The molecular pathogenesis of the myelodysplastic syndromes , 2015, European journal of haematology.

[16]  Carsten Peterson,et al.  Single-Cell Network Analysis Identifies DDIT3 as a Nodal Lineage Regulator in Hematopoiesis , 2015, Cell reports.

[17]  P. Campbell,et al.  Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes , 2015, Nature Communications.

[18]  A. Verma,et al.  Stem cell origin of myelodysplastic syndromes , 2014, Oncogene.

[19]  Randy J. Read,et al.  Transcriptional diversity during lineage commitment of human blood progenitors , 2014, Science.

[20]  Wei Li,et al.  Dnmt3a and Dnmt3b have overlapping and distinct functions in hematopoietic stem cells. , 2014, Cell stem cell.

[21]  I. Weissman,et al.  Quiescent hematopoietic stem cells accumulate DNA damage during aging that is repaired upon entry into cell cycle. , 2014, Cell stem cell.

[22]  S. Linnarsson,et al.  Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. , 2014, Cancer cell.

[23]  J. Li,et al.  Global transcriptome analyses of human and murine terminal erythroid differentiation. , 2014, Blood.

[24]  B. Göttgens,et al.  Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. , 2014, Cell stem cell.

[25]  M. Cazzola,et al.  Identification of gene expression-based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  E. Montecino-Rodriguez,et al.  Causes, consequences, and reversal of immune system aging. , 2013, The Journal of clinical investigation.

[27]  A. Raza,et al.  The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes , 2012, Nature Reviews Cancer.

[28]  Debashis Sahoo,et al.  Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with age , 2011, Proceedings of the National Academy of Sciences.

[29]  Mamoru Ito,et al.  Accumulation of oxidative DNA damage restricts the self-renewal capacity of human hematopoietic stem cells. , 2011, Blood.

[30]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[31]  J. Qian,et al.  Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome. , 2010, Leukemia research.

[32]  M Cazzola,et al.  Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells , 2010, Leukemia.

[33]  Robert Tibshirani,et al.  Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. , 2009, Blood.

[34]  Torsten Haferlach,et al.  Microarray-based classifiers and prognosis models identify subgroups with distinct clinical outcomes and high risk of AML transformation of myelodysplastic syndrome. , 2009, Blood.

[35]  M. Cazzola,et al.  Gene expression profiling of CD34+ cells in patients with the 5q− syndrome , 2007, British journal of haematology.

[36]  Li Wang,et al.  Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. , 2006, Blood.

[37]  J. Qian,et al.  Gene expression profiling of the bone marrow mononuclear cells from patients with myelodysplastic syndrome. , 2005, Oncology reports.

[38]  I. Weissman,et al.  Cell intrinsic alterations underlie hematopoietic stem cell aging. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  J. Rowe,et al.  The relationship of patient age to the pathobiology of the clonal myeloid diseases. , 2004, Seminars in oncology.

[40]  Y. Yamashita,et al.  DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome , 2003, British journal of haematology.

[41]  Y. Yamashita,et al.  Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. , 2001, Blood.

[42]  T. Flores,et al.  The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice , 2000, Oncogene.

[43]  F. Mitelman,et al.  Additional evidence of a variant translocation t(12;22) with EWS/CHOP fusion in myxoid liposarcoma: clinicopathological features , 1997, The Journal of pathology.

[44]  J. Qian,et al.  Decreased expression of CCAAT/enhancer binding protein zeta (C/EBPzeta) in patients with different myeloid diseases. , 2005, Leukemia research.

[45]  J. Léon,et al.  Revised Papers , 2003 .

[46]  H Phillip Koeffler,et al.  Myelodysplastic Bone Marrow Cells from Normal and + Characterization of Gene Expression of Cd34 , 2002 .